MEDIFAST, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.57 USD | +0.45% |
|
+5.30% | -50.06% |
| Feb. 20 | Medifast, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 20 | Transcript : Medifast, Inc., Q4 2023 Earnings Call, Feb 20, 2024 |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.26 for the 2024 fiscal year.
- The company has a low valuation given the cash flows generated by its activity.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -50.06% | 360M | C- | ||
| +6.96% | 7.59B | D+ | ||
| +5.49% | 5.93B | - | ||
| -8.63% | 3.66B | D | ||
| -13.28% | 3.38B | B- | ||
| -15.49% | 1.16B | - | - | |
| +10.65% | 979M | - | ||
| -39.71% | 922M | B+ | ||
| -18.47% | 861M | C+ | ||
| -17.52% | 800M | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MED Stock
- Ratings Medifast, Inc.
